You are here
News
Coverage of the latest news and updates from the field of stem cells and regenerative medicine.
May 28, 2020
LOS ANGELES, CA (US), May 2020 — An interdisciplinary team of researchers at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at University of California Los Angeles has developed a first-of-its-kind roadmap
May 27, 2020
KAZAN (RU), May 2020 — As we know, a malignant tumor is a complex system of mutated cells which constantly interacts with and involves healthy cells in the body.
May 26, 2020
FREIBURG (DE), May 2020 — On average, the human body contains 35 trillion red blood cells (RBCs). Approximately 3 million of these small disc-shaped cells die in one second.
May 21, 2020
BOSTON, MA (US), May 2020 — Scientists at the Stem Cell Research program at Boston Children's Hospital and Dana-Farber Cancer Institute/Harvard Medical School have devised a mouse model that lets researchers track every cell in the body, from th
May 21, 2020
BUFFALO, NY (US), May 2020 — A group of researchers at the University at Buffalo have published a paper that clarifies certain cellular mechanisms that could lead to improved outcomes in patients with globoid cell leukodystrophy, commonly known
May 21, 2020
LA JOLLA, CA (US), May 2020 — Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neu
May 18, 2020
SHEFFIELD (UK), May 2020 — Research from the University of Sheffield has given new insight into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring.
May 18, 2020
Cell Therapy Treatment for Cardiac Patients With Microvascular Dysfunction Provides Enhanced Quality
WASHINGTON DC (US), May 2020 — Trial results presented May 14 revealed a promising therapy for patients experiencing angina due to coronary microvascular dysfunction (CMD).
May 14, 2020
NEW YORK, NY (US), May 2020 — The first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States of Mesoblast Ltd.’s (Melbourne, Australia) allogeneic cellular medicine remestemcel-L in COVID
